Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy.
Department of Medicine of Systems, Tor Vergata University of Rome, 00133 Rome, Italy.
Viruses. 2023 Jan 10;15(1):193. doi: 10.3390/v15010193.
The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retrospective multicentre observational study was conducted on 160 PLWH switching to the 2DR-3TC-based regimen: 51 HBcAb-positive and 109 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly lower percentage of subjects with HIV viral suppression with target not detected (TND) at all time points after switching (24th month: 64.7% vs. 87.8%, p < 0.0001; 36th month 62.7% vs. 86.8%, p = 0.011; 48th month 57.2% vs. 86.1%, p = 0.021 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that the presence of HBcAb positivity (OR 7.46 [95% CI 2.35−14.77], p = 0.004) could favour the emergence of HIV viral rebound by nearly 54% during the entire study follow-up after switching to 2DR-3TC.
本研究旨在评估抗乙型肝炎病毒 (HBV) c 抗体（HBcAb 阳性）的存在是否会影响接受包含拉米夫定（3TC）的二联抗病毒治疗（2DR-3TC）转换的 HIV 感染者（PLWH）的 HIV 病毒血症控制。对 160 名转换为 2DR-3TC 方案的 PLWH 进行了回顾性多中心观察性研究：51 名 HBcAb 阳性和 109 名 HBcAb 阴性患者。HBcAb 阳性的 PLWH 组在转换后的所有时间点（24 个月：64.7% vs. 87.8%，p < 0.0001；36 个月：62.7% vs. 86.8%，p = 0.011；48 个月：57.2% vs. 86.1%，p = 0.021），HIV 病毒抑制达到目标不可检测（TND）的患者比例明显较低。逻辑回归分析显示，HBcAb 阳性（OR 7.46 [95%CI 2.35-14.77]，p = 0.004）在转换为 2DR-3TC 后的整个研究随访期间，可使 HIV 病毒反弹的出现率增加近 54%。
